Evidence map›Paper›PMID 26413498›Full record

ArticleJournal of cardiology and therapeutics2015

Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice.

Courtney Netherland-Van Dyke, Ward Rodgers, Makenzie Fulmer, Zachary Lahr, Douglas Thewke

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cardiology and therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2.Cardiovascular & hematological disorders drug targets · 2018
    Review
  2. The CBCellular and molecular life sciences : CMLS · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Courtney Netherland-Van DykeDepartment of Pathology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Ward RodgersDepartment of Biomedical Sciences, Center for Inflammation, Infectious Disease and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Makenzie FulmerDepartment of Biomedical Sciences, Center for Inflammation, Infectious Disease and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Zachary LahrDepartment of Biomedical Sciences, Center for Inflammation, Infectious Disease and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
Douglas ThewkeDepartment of Biomedical Sciences, Center for Inflammation, Infectious Disease and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, 37614, USA.
East Tennessee State University · US

Funding

Modulation of atherosclerosis by cannabinoid type 2 receptorR15HL113878 · NHLBI · EAST TENNESSEE STATE UNIVERSITY · PI THEWKE, DOUGLAS P · 2013 to 2013
$352k
The role of CB2 receptors in oxLDL-induced apopotosis and atherogenesisR15HL085137 · NHLBI · EAST TENNESSEE STATE UNIVERSITY · PI THEWKE, DOUGLAS P · 2006 to 2006
$219k
NHLBI NIH HHS R15 HL085137NHLBI NIH HHS R15 HL113878
6 · The paper itself

Abstract

purposeWIN55,212-2, a potent synthetic agonist of cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2), reduces atherosclerosis in apolipoprotein E (ApoE) null mice. Although pharmacologic evidence suggests the anti-atherosclerotic effects of WIN55,212-2 are mediated

methodsAfter 6 weeks on an atherogenic diet, groups of CB2

resultsPlasma cholesterol and triglyceride levels did not differ between CB2

conclusionsWIN55,212-2 treatment does not alter lesion size in Ldlr null-mice, but does modify lesion cellularity

Indexed as

AtherosclerosisCannabinoid ReceptorWIN55,212-2

Identifiers

PMID26413498
PMCPMC4581537
OpenAlexW2230881579

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.